参考文献
1.NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines): Testicular Cancer Version 1.2019-October 22, 2018.
2.American Joint Committee on Cancer(AJCC)Cancer Staging System(8th ed., 2017).
3.Sarici H, Telli O, Eroglu M.Bilateral testicular germ cell tumors.Turk J Urol 2013, 39: 249-252.
4.Ferraro S, Trevisiol C, Gion M, et al.Human chorionic gonadotropin assays for testicular tumors: closing the gap between clinical and laboratory practice.Clin Chem 2018, 64: 270-278.
5.Dieckmann KP, Anheuser P, Schmidt S, et al.Testicular prostheses in patients with testicular cancer-acceptance rate and patient satisfaction.BMC Urol 2015, 15: 16.
6.Robinson R, Tait CD, Clarke NW, et al.Is it safe to insert a testicular prosthesis at the time of radical orchidectomy for testis cancer: an audit of 904 men undergoing radical orchidectomy.BJU Int 2016, 117: 249-252.
7.Trevino K, Shandiz AE, Saeed O, et al.Pathologic risk factors for higher clinical stage in testicular seminomas.Histopathology 2018.
8.Daugaard G, Gundgaard MG, Mortensen MS, et al.Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort.J Clin Oncol 2014, 32: 3817-3823.
9.Tandstad T, Stahl O, Dahl O, et al.Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group(SWENOTECA).Ann Oncol 2016, 27: 1299-1304.
10.Boormans JL, Mayor de Castro J, Marconi L, et al.Testicular tumour size and rete testis invasion as prognostic factors for the risk of relapse of clinical stage I seminoma testis patients under surveillance: a systematic review by the Testicular Cancer Guidelines Panel.Eur Urol 2017.
11.Kollmannsberger C, Tandstad T, Bedard PL, et al.Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance.J Clin Oncol 2015, 33: 51-57.
12.Cohn-Cedermark G, Stahl O, Tandstad T.Surveillance vs.adjuvant therapy of clinical stage I testicular tumors-a review and the SWENOTECA experience.Andrology 2015, 3: 102-110.(https://www.daowen.com)
13.Dieckmann KP, Dralle-Filiz I, Matthies C, et al.Testicular seminoma clinical stage 1: treatment outcome on a routine care level.J Cancer Res Clin Oncol 2016, 142: 1599-1607.
14.Glaser SM, Vargo JA, Balasubramani GK, et al.Stage II testicular seminoma: patterns of care and survival by treatment strategy.Clin Oncol(R Coll Radiol)2016, 28: 513-521.
15.Chovanec M, Hanna N, Cary KC, et al.Management of stage I testicular germ cell tumours.Nat Rev Urol 2016, 13: 663-673.
16.Fung C, Dinh P, Jr., Ardeshir-Rouhani-Fard S, et al.Toxicities associated with cisplatin-based chemotherapy and radiotherapy in longterm testicular cancer survivors.Adv Urol 2018.
17.Kerns SL, Fung C, Monahan PO, et al.Cumulative burden of morbidity among testicular cancer survivors after standard cisplatin-based chemotherapy: a multiinstitutional study.J Clin Oncol 2018, 36: 1505-1512.
18.Schmidt AH, Hoyer M, Jensen BFS, et al.Limited postchemotherapy retroperitoneal resection of residual tumour in nonseminomatous testicular cancer: complications, outcome and quality of life.Acta Oncol 2018: 1-10.
19.Heidenreich A, Haidl F, Paffenholz P, et al.Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours.Ann Oncol 2017, 28: 362-367.
20.Oing C, Lorch A, Bokemeyer C.Ongoing clinical trials in testicular cancer: the TIGER trial.Oncol Res Treat 2016, 39: 553-556.
21.Seidel C, Oechsle K, Lorch A, et al.Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatinrefractory germ cell cancer in routine care-registry data from an outcomes research project of the German Testicular Cancer Study Group.Urol Oncol 2016, 34: 21-28.
22.Beard CJ, Travis LB, Chen MH, et al.Outcomes in stage I testicular seminoma: a population-based study of 9193 patients.Cancer 2013, 119: 2771-2777.
23.Sprauten M, Darrah TH, Peterson DR, et al.Impact of long-term serum platinum concentrations on neuro- and ototoxicity in cisplatin-treated survivors of testicular cancer.J Clin Oncol 2012, 30: 300-307.